We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
PVRI 2025 Rio – Abstract deadline extension
The submission deadline for submitting PVRI 2025 Rio abstracts has been extended! The best abstracts will be considered for travel awards and selected for oral presentations in our main programme. Submissions close 21 October 2024.
Nominations now open for PVRI Achievement Awards 2025
These annual awards are given in recognition of outstanding contributions to the field of pulmonary hypertension. The PVRI Lifetime Achievement Award 2025 and the PVRI Achievement Award 2025 will be presented at PVRI 2025 Rio. Nominate by 25 November 2024.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
The abstract submission deadline has been extended for PVRI 2025 Rio! All accepted abstracts will be published in our journal, and the best abstracts will be selected for oral presentations in our main programme. Make sure to submit before 21 October 2024!
Webinar presentations: Identification of arterial and venous morphologic markers in pulmonary arterial hypertension using CT imaging; The keto diet as treatment for pulmonary hypertension associated with obesity; Endothelial transdifferential from exacerbated inflammatory signaling in BMP9 in lung endothelium; The role of pericytes in the pathophysiology of pulmonary arterial hypertension
Webinar presentations: Cellular mechosignaling in pulmonary arterial hypertension; Sex differences in pulmonary arterial hypertension randomized clinical trials; Precapillary pulmonary hypertension and death from COVID-19; Estradiol and estrogen receptor protection of right ventricular function – role of apelin; Prostacyclin reverses right ventricular hypertrophy and dysfunction in severe PAH; Pulmonary vascular complications of heart failure with preserved ejection fraction
Therapeutic exercise has not been widely adopted in pediatric pulmonary hypertension (PH), despite adult data supporting its safety and efficacy. While physical limitations may prevent children with PH from participating in physical activity, other barriers to and facilitators of physical activity are unknown.
Although surgical and interventional therapy has emerged as the primary treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH), there remains a subset of patients who need medication therapy. This study aimed to evaluate the efficacy and safety outcomes of prostacyclin pathway vasodilators, providing further insight for clinical decision-making.
This study aimed to examine the influence of the Neuregulin-1 (NRG1)/ERBB4 signaling pathway on the function of human pulmonary artery endothelial cells (HPAECs) and investigate the underlying mechanisms. Enzyme-linked immunosorbent assay indicated that ERBB4 levels in the serum of patients with pulmonary embolism (PE) were significantly higher than those of healthy controls (p < 0.05).
These annual awards are given in recognition of outstanding contributions to the field of pulmonary hypertension. They celebrate notable achievements made by special individuals across the world. The PVRI Lifetime Achievement Award 2025 and the PVRI Achievement Award 2025 will be presented at PVRI 2025 Rio.
This World Heart Day, PVRI supports the WHF campaign calling for increased awareness, better healthcare policies and more funding for heart health research.
The PVRI launched the Pulmonary Hypertension Global Patient Survey (PH GPS) in October 2023 to help clinicians better understand the impacts of PH on patients. The first global survey of its kind was aimed at those living with PH and their carers.
The Aristotle Classes on PH & ACHD is a scientific event organised jointly by the Medical School of Aristotle University, Thessaloniki, Greece, the Heart Center at the University of Cologne, Germany and Royal Brompton & Harefield Hospitals, Imperial College, London, UK.